CTNNB1 (β-catenin) mutations in NSCLC: clinicogenomic characteristics, prognostic value and implications for therapy
Glaser, M.; von Levetzow, C.; Rasokat, A.; Prang, D.; Nogova, L.; Woempner, C.; Schmitz, J.; Bitter, E.; Terjung, I.; Eisert, A.; Fischer, R.; John, F.; Michels, S.; Riedel, R.; Ruge, L.; Scharpenseel, H.; Schulte, W.; Sommerwerck, U.; Siebolts, U.; Merkelbach-Bruse, S.; Buettner, R.; Wolf, J.; Scheffler, M.
Show abstract
Although mutations in CTNNB1 have long been associated with cancer, their impact in patients with non-small cell lung cancer (NSCLC) is not well understood. Beyond a potential role in the acquired resistance setting of EGFR-mutant NSCLC, little is known about the clinical and molecular characteristics of NSCLC patients harboring these mutations. Here, we identify 302/15,688 (1.9%) NSCLC patients with CTNNB1 mutations. These mutations frequently co-occur with EGFR and KRAS mutations and are associated with a favorable prognosis (mOS, 45.8 months overall; 19.7 months KRASmut). Patients benefit significantly from immune-checkpoint-blockade, but non-intuitively,PD-L1 TPS [≥]50%(4/6 treated with monotherapy) survive the shortest. We show that patients with proposed CTNNB1 resistance mutations to EGFR-directed therapy have significantly shorter mOS when treated with targeted therapy, compared to non-resistant CTNNB1 mutations. This study highlights unique clinicogenomic features and the nuanced impact of CTNNB1 mutations on therapeutic outcomes.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma 96%
- A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer 95%
- Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers 95%
Similar papers in this journal
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 95%
- Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence 94%
- Comprehensive analysis of mutational signatures in pediatric cancers 93%
Similar papers in this journal
- Propagated circulating tumor cells uncovers the rople of NFκB and COP1 in metastasis 94%
- The French Early Breast Cancer Cohort (FRESH): a resource for breast cancer research and evaluations of oncology practices based on the French National Healthcare System Database (SNDS) 93%
- Paradoxical role of AT-rich interactive domain 1A in restraining pancreatic carcinogenesis 93%
Similar papers in this journal
- Predicting the Tumor Microenvironment Composition and Immunotherapy Response in Non-Small Cell Lung Cancer from Digital Histopathology Images 95%
- Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations 93%
- Explainable, federated deep learning model predicts disease progression risk of cutaneous squamous cell carcinoma 93%
Similar papers in this journal
- RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236 94%
- Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up 94%
- Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.